{"id":"W4384926029","doi":"10.2217/fon-2023-0436","title":"Time to Next Treatment in Patients with Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib","year":2023,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Hazard ratio; Pharmacy; Leukemia; Confidence interval; Family medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003753136,0.000440953,0.0009579652,0.0005658058,0.000151988,0.00002976801,0.0002714754,0.0004605287,0.002249155],"category_scores_gemma":[0.0003694813,0.0002975866,0.0001042841,0.0019217,0.0001615905,0.0001223467,0.0002371507,0.0003703325,0.005639053],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.2130783,"about_ca_system_score_gemma":0.05347647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000619666,"about_ca_topic_score_gemma":0.001844842,"domain_scores_codex":[0.9965308,0.0001529039,0.0006335412,0.0007964884,0.0006115766,0.001274662],"domain_scores_gemma":[0.9977772,0.0007194873,0.0001465414,0.0006895733,0.0001735553,0.0004936754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.08333098,0.003295247,0.02693828,0.002728096,0.002155558,0.02432131,0.01453273,0.02891891,0.001245189,0.0002084609,0.1153487,0.6969765],"study_design_scores_gemma":[0.2472965,0.05518282,0.06759451,0.001042062,0.0003364511,0.0005351623,0.000740023,0.05696234,0.00062514,0.00002113215,0.5685405,0.001123356],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893793,0.0001219466,0.000004620776,0.002205257,0.0003163575,0.002357921,0.00003426005,0.0003112489,0.005269035],"genre_scores_gemma":[0.9814765,0.0002290404,0.0007281019,0.001634984,0.00238693,0.0006938768,0.0006377287,0.000174466,0.01203833],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6958532,"threshold_uncertainty_score":0.9999476,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02862538190468888,"score_gpt":0.3218995280787459,"score_spread":0.2932741461740571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}